Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis-inducing ligand level mediated by the p38 mitogen-activated protein kinase signaling pathway

被引:23
作者
Lub-de Hooge, MN
de Jong, S
Vermot-Desroches, C
Tulleken, JE
de Vries, EGE
Zijlstra, JG
机构
[1] Univ Groningen Hosp, Dept Hosp Pharm, NL-9713 GZ Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands
[3] Univ Groningen Hosp, Dept Intens & Resp Care, NL-9713 GZ Groningen, Netherlands
[4] Diaclone, Besancon, France
来源
SHOCK | 2004年 / 22卷 / 02期
关键词
endotoxemia; sepsis; TRAIL; apoptosis; p38; MAPK;
D O I
10.1097/01.shk.0000132486.82177.ec
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Despite extensive knowledge about the mechanisms behind sepsis, this syndrome still caries a large morbidity and mortality rate. Dysregulated immune and coagulation systems are held responsible. However, additional pathophysiological mechanisms such as uncontrolled apoptosis induced by death receptor ligands might well play a role. P38 mitogen-activated protein (MAP) kinase inhibitors are considered as potential drugs in inflammatory diseases. Therefore, the effect of endotoxin administration on the response of soluble(s) tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL), a death receptor ligand, and the role of p38 MAP kinase inhibition was studied in 21 human volunteers. The volunteers received 30 min before the endotoxin infusion a single oral dose of placebo or the selective p38 MAP kinase inhibitor drug, RWJ-67657. Plasma sTRAIL increased 10-fold to 6564 +/- 511 pg/mL after 2.5 h. This increase was blocked completely by the highest dose of RW-J6765. This is the first report showing that endotoxin increases sTRAIL where the p38 MAP kinase signaling pathway is involved.
引用
收藏
页码:186 / 188
页数:3
相关论文
共 28 条
[1]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[2]   Mechanisms of immune resolution [J].
Ayala, A ;
Chung, CS ;
Grutkoski, PS ;
Song, GY .
CRITICAL CARE MEDICINE, 2003, 31 (08) :S558-S571
[3]   Pathological aspects of apoptosis in severe sepsis and shock? [J].
Ayala, A ;
Lomas, JL ;
Grutkoski, PS ;
Chung, CS .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (01) :7-15
[4]   Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis [J].
Bernard, GR ;
Ely, EW ;
Wright, TJ ;
Fraiz, J ;
Stasek, JE ;
Russell, JA ;
Mayers, I ;
Rosenfeld, BA ;
Morris, PE ;
Yan, SB ;
Helterbrand, JD .
CRITICAL CARE MEDICINE, 2001, 29 (11) :2051-2059
[5]   Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity [J].
Chung, CS ;
Song, GY ;
Lomas, J ;
Simms, HH ;
Chaudry, IH ;
Ayala, A .
JOURNAL OF LEUKOCYTE BIOLOGY, 2003, 74 (03) :344-351
[6]   Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge:: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness [J].
Faas, MM ;
Moes, H ;
Fijen, JW ;
Kobold, ACM ;
Tulleken, JE ;
Zijlstra, JG .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 127 (02) :337-343
[7]   Inhibition of p38 mitogen-activated protein kinase: Dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans [J].
Fijen, JW ;
Tulleken, JE ;
Kobold, ACM ;
de Boer, P ;
van der Werf, TS ;
Ligtenberg, JJM ;
Spanjersberg, R ;
Zijlstra, JG .
CRITICAL CARE MEDICINE, 2002, 30 (04) :841-845
[8]   Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers [J].
Fijen, JW ;
Zijlstra, JG ;
De Boer, P ;
Spanjersberg, R ;
Tervaert, JWC ;
Van der Werf, TS ;
Ligtenberg, JJM ;
Tulleken, JE .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 124 (01) :16-20
[9]   Meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis [J].
Freeman, BD ;
Zehnbauer, BA ;
Buchman, TG .
SHOCK, 2003, 20 (01) :5-9
[10]  
Halaas O, 2000, SCAND J IMMUNOL, V51, P244